Mohammed Rassool to Tuberculosis, Pulmonary
This is a "connection" page, showing publications Mohammed Rassool has written about Tuberculosis, Pulmonary.
Connection Strength
0,786
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,181
-
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis. Trials. 2023 Jun 06; 24(1):382.
Score: 0,170
-
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 12 22; 387(25):2331-2343.
Score: 0,164
-
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 08; 9(8):897-908.
Score: 0,145
-
Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa. J Neurovirol. 2012 Jun; 18(3):162-71.
Score: 0,078
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
Score: 0,048